Skip to main navigation

Compass Therapeutics

Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact

News Releases

Investor Menu

Home
News & Events
Stock Information
Corporate Governance
Financial & FIlings

Year

Sep 03, 2024

Compass Therapeutics to Participate in Upcoming Investor Events

Additional Formats

PDF Version

Aug 12, 2024

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

Additional Formats

PDF Version

Aug 07, 2024

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Additional Formats

PDF Version

Aug 06, 2024

Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer

Additional Formats

PDF Version

May 30, 2024

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Additional Formats

PDF Version

May 28, 2024

Compass Therapeutics Announces CEO Transition

Additional Formats

PDF Version

May 23, 2024

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Additional Formats

PDF Version

May 14, 2024

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Additional Formats

PDF Version

May 13, 2024

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Additional Formats

PDF Version

Apr 25, 2024

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Additional Formats

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18

IR Contact

IR@compasstherapeutics.com

Media Contact

Anna Gifford, Senior Communications Manager

Anna.Gifford@compasstherapeutics.com

Email Alerts

© 2024 Compass Therapeutics, Inc.
Terms & Conditions
Privacy Policy

Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact